axitinib,sunitinib,pembrolizumab,Lenvatinib,Everolimus,Atezolizumab,Cabozantinib
pfizer,merck,Eisai,roche
['prostate', 'bms']
 great resume!.i have a feeling that imdc falls short in era of combos. eg. time f dx to systx or ks could be unreliable. hb seems ok. until we find molecular bms, do you believe we should re-think the clinical risk factors (eg, de-novo, inflam mrks, etc)? like prostate.
Medical oncologist interested in #GUcancers and #Rstat | Views my own. 🇵🇪 🇪🇸